IL1A and Arthritis: It was also shown that mast cells in the initiation phase of the disease were activated through FcγRIII, which led to release of IL-1 (47), and arthritis could be suppressed by preventing the activation-induced degranulation of mast cells by treatment with the cAMP-inducing agent, salbutamol (48).